Research - Planegg, Bavaria, Germany
ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich.At ViGeneron we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms.ViGeneron will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders.Together with partners we will exploit our ViGeneron technologies for additional indications.
Outlook
Apache
WordPress.org
Mobile Friendly